-
Dr. Andrea Mastrangelo Explores Unique CD8 T Cell Responses in HIV Controllers | hashtag CROI2025
New research led by Dr. Andrea Mastrangelo at Centre Hospitalier Universitaire Vaudois unveils a distinct transcriptomic signature in lymph node (LN) HIV-specific CD8 T cells of HIV controllers. Unlike chronic HIV-infected individuals (CHI), controllers exhibited an enriched population of stem-like CD8 T cells marked by TCF7, IL7R, and BACH2, which may contribute to proliferative potential…
-
Investigating the Evolution of Global and Endemic Clade II MPXV | Dr. Rebecca P Sumner at hashtag CROI2025
New research from Dr. Rebecca P Sumner at the University of Surrey uncovers key biological differences between the global MPXV lineage B and its ancestral lineage A, which remains endemic in Africa.
-
SGBCC 2025 | Dr. Cynthia Villarreal-Garza: Monitoring and Management of Long-term Toxicities in Young Breast Cancer Patients
The impact of long-term toxicity management on patient quality of life is increasingly being recognized in breast cancer treatment. At the recently held 19th St. Gallen Breast Cancer Conference (SGBCC 2025), Dr. Cynthia Villarreal-Garza, Director of Clinic Oncology at the Breast Cancer Center, TecSalud,delivered a presentation titled “Ensuring Long-term Healthy Survival of Breast Cancer Patients.”…
-
JOH | A New Prognostic Indicator for Post-TIPS Survival Risk – The Freiburg Index
Recently, an important study by the German Liver Cirrhosis Research Group (DGVS) introduced the Freiburg Index (FIPS), which integrates age, serum creatinine, bilirubin, and albumin levels to effectively identify high-risk…
-
POST-ASCO GI丨2025 From Following to Leading Dr. Yanhong Deng on China’s Breakthroughs in Colorectal Cancer Molecular Classification and a New Paradigm
In this exclusive interview, Professor Deng reflects on the evolution of the POST-ASCO GI meeting, now in its 11th year, as a bridge between global advancements and domestic practice. She…
-
2025 North-South Summit | Dr. Man Li: Treatment Optimization and Strategic Advancements for HR+/HER2- Breast Cancer Patients
Oncology Frontier: CDK4/6 inhibitors have shown significant efficacy in the treatment of HR+/HER2- advanced breast cancer. How do you view the role of CDK4/6 inhibitors in future treatment strategies? Are…
-
Academician Binghe Xu: Clinical Research Advances in Breast Cancer in China and the Outlook for the SGBCC Conference
Oncology Frontier: At this conference, you gave a lecture titled “Advances and Outlook of Breast Cancer Drug Clinical Research in China.” Could you summarize your lecture and share the key…
-
ASCO GU 2025 | Dr. Philip Kwong: Precision Testing and Individualized Management in mCRPC
The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was held in San Francisco, California, from February 13 to 15. It attracted top experts and scholars in the field of urology from around the world. At this conference, Oncology Frontier invited Dr. Philip Kwong from The University of Hong Kong to share…
Connecting Medical Expertise through Media